Mesenchymal stromal cells (MSC) possess several fairly unique properties that, combined, make them ideally suited for cellular-based immunotherapy and as vehicles for gene and drug delivery for a wide range of diseases/disorders. Key among these are: 1) their relative ease of isolation from a variety of tissues; 2) the ability to be expanded in culture
Stem cells derived from a patient’s own fat offer a step toward improving—not just stabilizing—motor and sensory function of people with spinal cord injuries, according to early research from Mayo Clinic. A clinical trial enrolled 10 adults to treat paralysis from traumatic spinal cord injury. After stem cell injection, the first patient demonstrated improvement in motor
Therapy shown to relieve extreme pain in mice. Now moving towards human trials. Human stem cells and “pain-killing neurons” have successfully relieved chronic pain in mice. The breakthrough method may be tested on human patients suffering untreatable pain within five years. Researchers at the University of Sydney have used human stem cells to make pain-killing
New data released shows cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector. Additional 6,000m2 of cell and gene therapy manufacturing space expected to become available within the next 12 months. The Cell and Gene Therapy Catapult (CGT Catapult) published the sixth annual UK cell and gene therapy
MULTIPLE sclerosis campaigners have hailed a “huge step forward” for patients in Scotland after a stem cell therapy was recommended for use on the NHS for the first time. Haematopoietic stem cell transplantation (HSCT) has been described as a “game-changer” for MS after an international clinical trial showed that it could reboot patients’ immune systems and halt the progress
Scientists of John Hopkins University School of Medicine summarize the current methods of human pluripotent stem cells (HPSCs) myogenic commitment/differentiation, and describe the current status of hPSC-derived myogenic cell transplantation. Muscular dystrophies are a group of genetic muscle disorders that cause progressive muscle weakness and degeneration. Within this group, Duchenne muscular dystrophy (DMD) is the
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease and Lou Gehrig’s disease, is a rare condition characterized by the degeneration of nerve cells that control voluntary muscles. The disease leads to gradually worsening symptoms that include muscle weakness, twitching, and stiffness. As more of these nerve cells, or motor neurons, are lost, muscles decrease in size
By Annie Hubert, Senior Director, European Public Policy at Alliance for Regenerative Medicine ATMPs are varied and complex, ranging from potential one-off curative treatments to treatments tailored to a specific individual. As such, they differ significantly from ‘traditional’ medicinal treatments, something which has been recognised by regulators in Europe: the European Parliament introduced ATMPs as a
Liver disease patients could one day benefit from a new cell therapy that has just completed its first clinical trial, published in Nature Medicine. Researchers of MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK who tested the potential treatment in patients with liver cirrhosis – where long term damage produces scarring – found
Terumo BCT’s latest cell therapy technology, the Finia® Fill and Finish System, is a first-of-its-kind device developed to help bring reproducibility and control to cell therapy manufacturing to get therapies to more patients who need them. Finia is a fully automated, modular, functionally closed system that creates the final formulation of cell and gene therapies
